Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells

Ronit I. Yarden, Andrea H. Lauber, Dorraya El-Ashry, Susan A. Chrysogelos

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

In breast cancer, epidermal growth factor (EGF) receptor (EGFR) expression is inversely correlated with expression of estrogen receptor (ER) and predicts the prognosis and failure of endocrine therapy. We report here, for the first time, that in ER-positive breast cancer cell lines, MCF-7, T47D, and BT474, 17β-estradiol (E2) transiently induced EGFR messenger RNA (mRNA) levels 2- to 3-fold; this induction was prevented by the presence of the antiestrogen ICI 164,384 and was also reflected in the level of EGFR protein. Up-regulation of EGFR mRNA is most likely due to a direct effect of ER on the EGFR gene, with no involvement of protein synthesis, as it was not inhibited in the presence of cycloheximide; however, the subsequent down-regulation of EGFR required de novo protein synthesis. E2 had no effect on EGFR mRNA stability, and EGFR transcript levels were found to parallel EGFR mRNA levels, further supporting a direct transcriptional mechanism in the regulation of EGFR expression by estrogens. Additionally, sequencing of the EGFR promoter revealed putative imperfect estrogen-responsive elements that were capable of binding human ER. The transient nature of EGFR induction by E2, with a rapid return to a basal level that is dependent on protein synthesis, suggests that breast cancer cells possess active mechanisms to maintain low levels of EGFR expression in the presence of estrogen and a functional ER.

Original languageEnglish
Pages (from-to)2739-2747
Number of pages9
JournalEndocrinology
Volume137
Issue number7
DOIs
StatePublished - Jul 5 1996
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Estrogens
Breast Neoplasms
Estrogen Receptors
Messenger RNA
Proteins
Estrogen Receptor Modulators
RNA Stability
Cycloheximide
Estradiol
Up-Regulation
Down-Regulation
Cell Line

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Yarden, R. I., Lauber, A. H., El-Ashry, D., & Chrysogelos, S. A. (1996). Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology, 137(7), 2739-2747. https://doi.org/10.1210/en.137.7.2739

Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. / Yarden, Ronit I.; Lauber, Andrea H.; El-Ashry, Dorraya; Chrysogelos, Susan A.

In: Endocrinology, Vol. 137, No. 7, 05.07.1996, p. 2739-2747.

Research output: Contribution to journalArticle

Yarden, RI, Lauber, AH, El-Ashry, D & Chrysogelos, SA 1996, 'Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells', Endocrinology, vol. 137, no. 7, pp. 2739-2747. https://doi.org/10.1210/en.137.7.2739
Yarden, Ronit I. ; Lauber, Andrea H. ; El-Ashry, Dorraya ; Chrysogelos, Susan A. / Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. In: Endocrinology. 1996 ; Vol. 137, No. 7. pp. 2739-2747.
@article{d49518d5f46a4e618b2853a11aa5e059,
title = "Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells",
abstract = "In breast cancer, epidermal growth factor (EGF) receptor (EGFR) expression is inversely correlated with expression of estrogen receptor (ER) and predicts the prognosis and failure of endocrine therapy. We report here, for the first time, that in ER-positive breast cancer cell lines, MCF-7, T47D, and BT474, 17β-estradiol (E2) transiently induced EGFR messenger RNA (mRNA) levels 2- to 3-fold; this induction was prevented by the presence of the antiestrogen ICI 164,384 and was also reflected in the level of EGFR protein. Up-regulation of EGFR mRNA is most likely due to a direct effect of ER on the EGFR gene, with no involvement of protein synthesis, as it was not inhibited in the presence of cycloheximide; however, the subsequent down-regulation of EGFR required de novo protein synthesis. E2 had no effect on EGFR mRNA stability, and EGFR transcript levels were found to parallel EGFR mRNA levels, further supporting a direct transcriptional mechanism in the regulation of EGFR expression by estrogens. Additionally, sequencing of the EGFR promoter revealed putative imperfect estrogen-responsive elements that were capable of binding human ER. The transient nature of EGFR induction by E2, with a rapid return to a basal level that is dependent on protein synthesis, suggests that breast cancer cells possess active mechanisms to maintain low levels of EGFR expression in the presence of estrogen and a functional ER.",
author = "Yarden, {Ronit I.} and Lauber, {Andrea H.} and Dorraya El-Ashry and Chrysogelos, {Susan A.}",
year = "1996",
month = "7",
day = "5",
doi = "10.1210/en.137.7.2739",
language = "English",
volume = "137",
pages = "2739--2747",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells

AU - Yarden, Ronit I.

AU - Lauber, Andrea H.

AU - El-Ashry, Dorraya

AU - Chrysogelos, Susan A.

PY - 1996/7/5

Y1 - 1996/7/5

N2 - In breast cancer, epidermal growth factor (EGF) receptor (EGFR) expression is inversely correlated with expression of estrogen receptor (ER) and predicts the prognosis and failure of endocrine therapy. We report here, for the first time, that in ER-positive breast cancer cell lines, MCF-7, T47D, and BT474, 17β-estradiol (E2) transiently induced EGFR messenger RNA (mRNA) levels 2- to 3-fold; this induction was prevented by the presence of the antiestrogen ICI 164,384 and was also reflected in the level of EGFR protein. Up-regulation of EGFR mRNA is most likely due to a direct effect of ER on the EGFR gene, with no involvement of protein synthesis, as it was not inhibited in the presence of cycloheximide; however, the subsequent down-regulation of EGFR required de novo protein synthesis. E2 had no effect on EGFR mRNA stability, and EGFR transcript levels were found to parallel EGFR mRNA levels, further supporting a direct transcriptional mechanism in the regulation of EGFR expression by estrogens. Additionally, sequencing of the EGFR promoter revealed putative imperfect estrogen-responsive elements that were capable of binding human ER. The transient nature of EGFR induction by E2, with a rapid return to a basal level that is dependent on protein synthesis, suggests that breast cancer cells possess active mechanisms to maintain low levels of EGFR expression in the presence of estrogen and a functional ER.

AB - In breast cancer, epidermal growth factor (EGF) receptor (EGFR) expression is inversely correlated with expression of estrogen receptor (ER) and predicts the prognosis and failure of endocrine therapy. We report here, for the first time, that in ER-positive breast cancer cell lines, MCF-7, T47D, and BT474, 17β-estradiol (E2) transiently induced EGFR messenger RNA (mRNA) levels 2- to 3-fold; this induction was prevented by the presence of the antiestrogen ICI 164,384 and was also reflected in the level of EGFR protein. Up-regulation of EGFR mRNA is most likely due to a direct effect of ER on the EGFR gene, with no involvement of protein synthesis, as it was not inhibited in the presence of cycloheximide; however, the subsequent down-regulation of EGFR required de novo protein synthesis. E2 had no effect on EGFR mRNA stability, and EGFR transcript levels were found to parallel EGFR mRNA levels, further supporting a direct transcriptional mechanism in the regulation of EGFR expression by estrogens. Additionally, sequencing of the EGFR promoter revealed putative imperfect estrogen-responsive elements that were capable of binding human ER. The transient nature of EGFR induction by E2, with a rapid return to a basal level that is dependent on protein synthesis, suggests that breast cancer cells possess active mechanisms to maintain low levels of EGFR expression in the presence of estrogen and a functional ER.

UR - http://www.scopus.com/inward/record.url?scp=0030010812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030010812&partnerID=8YFLogxK

U2 - 10.1210/en.137.7.2739

DO - 10.1210/en.137.7.2739

M3 - Article

C2 - 8770893

AN - SCOPUS:0030010812

VL - 137

SP - 2739

EP - 2747

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 7

ER -